Publicis Touchpoint sol. partnered to build marketing team

[Deleted]

Looks like MNKD has outsourced the hiring to Publicis

60 positions listed

touchpointsolutions.jobs/jobs/?q=mannkind


Pharmaceutical Area Business Manager



Publicis Touchpoint Solutions, a division of Publicis Healthcare Communications Group, has partnered with MannKind Corporation to build a team of Pharmaceutical Area Business Manager (ABM) for an exciting launch of an innovative treatment for diabetes.



The Pharmaceutical Area Business Manager (ABM) will engage Health Care Professionals (HCPs) in face to face discussions to promote Afrezza, maximize selling potential, and meet program and Client objectives. The ABM achieves this by developing and maintaining relationships with HCPs and educating them about product features, benefits, safety profile and approved indications to ensure appropriate patient use. The ABM utilizes approved tools and resources for Afrezza promotion and maintains a competent level of product, territory, and customer activity knowledge. ABM will report into a Touchpoint Regional Field Coordinator and a MannKind Regional Sales Manager.



MannKind Corporation aspires to aid the community in leading a healthy life through two parallel objectives: formulating, developing and commercializing medicines, and delivering affordable and accessible medication that satisfies urgent medical needs.''

touchpointsolutions.jobs/philadelphia-pa/pharmaceutical-area-business-manager-philadelphia-pa/38DF425013E54B6BBB01036D5C4008B4/job/

[end2war]

This looks like a very convincing indicator that MNKD will have the funding to launch a US sales team. That implies some deal is coming to the rescue. It is not looking good for the short-sellers. 

[coo2002coo]

60 jobs out there to be filled.  That's quite impressive.

[maxbioinvestor]

Great news!

[uvula]

Might be another typo. Are we sure it is 60 positions and not 6?

[nylefty]

This is the most encouraging news I've seen in long time.

[mcgovernk]

touchpointsolutions.jobs/jobs/#2

It looks like more than 60 according to their posting. I don't post much, so I hope the link works. Quite an impressive number of reps.

[coo2002coo]

Apr 18, 2016 10:22:06 GMT -5 uvula said:

Might be another typo. Are we sure it is 60 positions and not 6?

You can count with ALL your figures and toes three time to see if the number fits 60.

[Deleted]

Each and every Mannkind sales position including geography.

touchpointsolutions.jobs/jobs/?q=Pharmaceutical+Area+Business+Manager

[nylefty]

Apr 18, 2016 10:22:58 GMT -5 mcgovernk said:

touchpointsolutions.jobs/jobs/#2

It looks like more than 60 according to their posting. I don't post much, so I hope the link works. Quite an impressive number of reps.

That  link works, but you didn't filter for MannKind listings.  If you do that, 60 jobs are listed. 

[Deleted]

Great find. Really encouraging news.

[coo2002coo]

Pricing strategy, I believed, has been revisited and re-set by MNKD after the return of Afrezza. Hopefully this time we will have a much stronger script numbers after the new launch in .... Q3?

[bradleysbest]

If true on lower pricing set.... Great news!

[babaoriley]

This is great news! Does anyone know the kind of bite these guys take?

end2war, "It is not looking good for the short-sellers." You've only had 12 posts, so I guess I ought to cut you some slack on that statement. Far more experienced folk than you have certainly held that view for many years.  

So, seems to me that more than a few here should be applying for those regional sales manager jobs; I think many are well-qualified - you retirees, get out there!

[longinvstr]

Progress ... I couldn't be more encouraged by this news!

I also think it's interesting to note which "weakness" the other side has chosen to be their target/subject du jour.  It's almost as if they have an if/then flow-chart that leads them to the next play.  Most recently, it has been financing and certain bankruptcy in 3rd Q.  Now, given this & other developments, that seems improbable.  So, their chart indicates that they should focus on superiority/new trial and subscription/patient retention.  To me, logic dictates that cost drove retention levels.  When free samples and Rx discount cards were exhausted, patients moved on (or back) to the economical choice.  That's rational.  MNKD will fix price and that will cure the insurance coverage gap.  Logic points to that as the remedy for any retention issues.

The Winter months did not have me feeling very rational about my investment in MNKD.  In every game tho, one case sense a momentum shift - the detection of advantage change prior to a score.  We're there; in this game, the irrational grasping has now become the purvey of the shorts.  We are on the cusp of a score!